poisar

Stocks · News reference

8-K filing — Dare Bioscience, Inc. (DARE)

SEC EDGARJul 17, 2026, 8:07 PMSEC EDGAR

Filed: 2026-07-17 AccNo: 0001401914-26-000040 Size: 140 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Jul 17, 2026, 8:07 PM
Checked
Jul 17, 2026, 8:07 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaAug 26, 2026, 12:47 PMBenzinga Newsdesk

    Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure

    The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"

    Read original at benzinga